Jianfeng Group announced that the subsidiary Jianfeng Pharmaceutical received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” from the State Drug Administration regarding the chemical ingredient cefmetoxime hydrochloride, indicating that the API has met the relevant national API evaluation technical standards, and that process optimization and consistency evaluation of injectable generic drugs have been approved. Jianfeng Pharmaceutical invested a total of about 8,511,000 yuan in research and development of the consistency evaluation project for cefmetoxime hydrochloride APIs and injections. Obtaining approval this time is beneficial to improving market competitiveness, but pharmaceutical products have the characteristics of high risk and high added value, and drug production and sales are easily affected by factors such as policies and market environment changes, and there is great uncertainty.